Frontline Quadruplet Therapy in NDMM: GRIFFIN and MASTER Studies
Expert perspectives on frontline daratumumab-containing quadruplet regimens in the context of recent clinical trials in newly diagnosed multiple myeloma.
Maintenance Therapy Duration and Considerations for Treatment Interruption
Experts comment on the typical urothelial cancer maintenance therapy duration in their practice, and situations in which they might consider interrupting treatment while maintaining patient response.
Treatment for Cisplatin-Ineligible Patients with High PD-L1 Expression
Petros Grivas, MD, PhD, shares a clinical scenario of a cisplatin-ineligible patient with high PD-L1 expression and lymph node metastases, and experts weigh in on recommended treatment options.
Use of Inotuzumab for ALL in the Frontline Setting
Nikesh Shah, MD, presents a trial published in Lancet Oncology in 2018 on the use of inotuzumab plus mini-CVD in the frontline setting for older patients with ALL.
Team Introductions: The Moffitt Marrowvingians vs The Memorial Sloan-Kettering Mavericks
Steven Frommeyer kicks off a new and exciting competitive series from CancerNetwork® and introduces the first 2 teams.
Common Adverse Events with Single-Agent or Combination Therapy
Mehmet Asim Bilen, MD, provides an overview of commonly observed adverse events in patients with metastatic RCC receiving single-agent or combination therapy.
Introduction and CIRCULATE-Japan Overview
May 5th 2022Stacey A. Cohen, MD, and Mark Lewis, MD, introduce the 2022 ASCO GI abstract, “Association of Circulating Tumor DNA Dynamics With Clinical Outcomes in the Adjuvant Setting for Patients With Colorectal Cancer From an Observational GALAXY Study in CIRCULATE-Japan.”